{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:16:47Z","timestamp":1792793807985,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, and cardiovascular disease remains the leading cause of death in this population. Statins are therefore a cornerstone of therapy in MASLD because of their antiatherosclerotic efficacy. Less attention has been paid to the possibility that part of the hepatic benefit observed in MASLD cohorts\u2014including lower aminotransferase levels, slower fibrosis progression, reduced decompensation and lower hepatocellular carcinoma incidence\u2014may reflect direct hepatic effects beyond LDL reduction. Although the evidence is predominantly observational, the direction and magnitude of the association have remained broadly consistent across independent cohorts. Recent studies have strengthened this signal, including a\n                    <jats:italic>post hoc<\/jats:italic>\n                    analysis of the PROSPER trial showing attenuation of excess mortality in individuals with elevated FIB-4, and a large Veterans Affairs cohort demonstrating a dose-dependent association between cumulative statin exposure and lower primary liver cancer risk in MASLD. This review integrates the preclinical, observational and indirect randomized evidence supporting the biological plausibility of liver-directed effects of statins. Mechanistically, the argument centres on inhibition of the mevalonate pathway as a molecular hub linking lipotoxicity, NLRP3-dependent inflammation, fibrogenesis and carcinogenesis through impaired prenylation of small GTPases. A fifth axis, intrahepatic hemodynamics mediated through KLF2\/eNOS signaling, is supported by randomized evidence in compensated cirrhosis. In contrast, the LIVERHOPE-EFFICACY trial showed no benefit in decompensated cirrhosis, helping define the therapeutic window. Within the limitations of the available evidence, we propose a conceptual reframing: in MASLD, statins may act not only as cardiovascular drugs, but also as agents with potentially relevant hepatic effects mediated through a shared molecular substrate.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1884657","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:56:28Z","timestamp":1784811388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.3389","volume":"17","author":[{"given":"Carolina","family":"Jim\u00e9nez-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqu\u00e9s de Valdecilla University Hospital","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Iruzubieta","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqu\u00e9s de Valdecilla University Hospital","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alonso-Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqu\u00e9s de Valdecilla University Hospital","place":["Santander, Spain"]},{"name":"Departamento de Anatom\u00eda y Biolog\u00eda Celular, Universidad de Cantabria","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Cay\u00f3n","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqu\u00e9s de Valdecilla University Hospital","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[{"name":"Cantabria Cohort, Valdecilla Research Institute (IDIVAL), Marqu\u00e9s de Valdecilla University Hospita","place":["Santander, Spain"]},{"name":"School of Medicine, University of Cantabria","place":["Santander, Spain"]},{"name":"Medicine AI","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2020.11.010","article-title":"Statins and lower mortality in rheumatic diseases: an effect of immortal time bias?","volume":"51","author":"Abrahami","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cbi.2017.06.026","article-title":"The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: a review of molecular mechanisms","volume":"273","author":"Ahmadi","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104621","DOI":"10.1016\/j.phrs.2019.104621","article-title":"The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; new functions for statins","volume":"152","author":"Ahmadi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e10446","DOI":"10.7759\/cureus.10446","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"G239","DOI":"10.1152\/ajpgi.00089.2023","article-title":"Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through rho-mediated modulation of actin cytoskeleton","volume":"325","author":"Benhammou","year":"2023","journal-title":"Am. J. Physiology-Gastrointestinal Liver Physiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20183","DOI":"10.1038\/s41598-019-56366-2","article-title":"Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH","volume":"9","author":"Bravo","year":"2019","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/aje\/kwm070","article-title":"Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect","volume":"166","author":"Brookhart","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/jim-2016-000092","article-title":"Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in Statin-Na\u00efVe patients with hypertension with atherosclerosis","volume":"64","author":"Chang","year":"2016","journal-title":"J. Investigative Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100740","DOI":"10.1016\/j.jhepr.2023.100740","article-title":"Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure","volume":"5","author":"Chapin","year":"2023","journal-title":"JHEP Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/wrr.12878","article-title":"Statin treatment and hypertrophic scarring after cardiac surgery","volume":"29","author":"Chello","year":"2021","journal-title":"Wound Repair Regen."},{"key":"B14","doi-asserted-by":"publisher","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/medsci14010084","article-title":"Efficacy and safety of statins in MASLD and other chronic liver diseases","volume":"14","author":"Commins","year":"2026","journal-title":"Med. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101337","DOI":"10.1016\/j.jhepr.2025.101337","article-title":"Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: post hoc analysis of the PROSPER trial","volume":"7","author":"de Jong","year":"2025","journal-title":"JHEP Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/cancers12040874","article-title":"Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis","volume":"12","author":"Facciorusso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/nejmoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.3390\/ijms24097818","article-title":"Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-Leiden mice by reducing hepatic inflammation","volume":"24","author":"Inia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1194\/jlr.M034876","article-title":"Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis","volume":"54","author":"Ioannou","year":"2013","journal-title":"J. Lipid Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1194\/jlr.M072454","article-title":"Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH","volume":"58","author":"Ioannou","year":"2017","journal-title":"J. Lipid Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"100330","DOI":"10.1016\/j.jlr.2023.100330","article-title":"Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH","volume":"64","author":"Ioannou","year":"2023","journal-title":"J. Lipid Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1194\/jlr.M063412","article-title":"Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1\u03b1-dependent manner","volume":"57","author":"Kakazu","year":"2016","journal-title":"J. Lipid Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"12615","DOI":"10.1038\/s41598-026-43347-5","article-title":"Statin use and the risk of liver-related events in older adults with steatotic liver disease","volume":"16","author":"Kang","year":"2026","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.cct.2021.106367","article-title":"SACRED: effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: statins and cirrhosis: reducing events of decompensation","volume":"104","author":"Kaplan","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/cancers18071132","article-title":"Association of statin use with reduced primary liver cancer risk, independent of age and cirrhosis protection in MASLD","volume":"18","author":"Karachaliou","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35732","DOI":"10.1038\/srep35732","article-title":"SREBP-2\/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1002\/hep4.1991","article-title":"Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature","volume":"6","author":"Kim","year":"2022","journal-title":"Hepatol. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/thoraxjnl-2016-208819","article-title":"Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis","volume":"72","author":"Kreuter","year":"2017","journal-title":"Thorax"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10595","DOI":"10.3390\/ijms251910595","article-title":"Non-alcoholic fatty liver disease and coronary artery disease: a bidirectional association based on endothelial dysfunction","volume":"25","author":"Ktenopoulos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.annepidem.2008.12.013","article-title":"Age-period-cohort analysis of hepatocellular carcinoma mortality in Taiwan, 1976\u20132005","volume":"19","author":"Lee","year":"2009","journal-title":"Ann. Epidemiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a veterans affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70256","DOI":"10.1111\/liv.70256","article-title":"Glucagon\u2010like Peptide\u20101 receptor agonists improve MASH and liver fibrosis: a meta\u2010analysis of randomised controlled trials","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial\u2013stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"B39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","article-title":"Isoprenylated proteins","volume":"63","author":"McTaggart","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3748\/wjg.v22.i3.1260","article-title":"Pharmacokinetic drug interactions in liver disease: an update","volume":"22","author":"Palatini","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jval.2010.10.033","article-title":"The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101764","DOI":"10.1016\/j.jhepr.2026.101764","article-title":"Underuse of statins in MASLD despite population-based associations with lower liver stiffness","volume":"8","author":"Pustjens","year":"2026","journal-title":"JHEP Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiology-Gastrointestinal Liver Physiology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e001404","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J. Gen. Intern Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","author":"Sorrentino","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"815882","DOI":"10.3389\/fphar.2022.815882","article-title":"Statin therapy for hyperlipidemic patients with chronic kidney disease and end-stage renal disease: a retrospective cohort study based on 925,418 adults in Taiwan","volume":"13","author":"Sung","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B58","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.14744\/hf.2025.02335","article-title":"Impact of statins on liver transaminases in patients with metabolic dysfunction\u2013associated steatotic liver disease: a 12-month retrospective review","volume":"7","author":"Wong","year":"2025","journal-title":"Hepatol. Forum"},{"key":"B60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7326\/M24-0004","article-title":"Benefits and risks associated with statin therapy for primary prevention in old and very old adults","volume":"177","author":"Xu","year":"2024","journal-title":"Ann. Intern Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"101313","DOI":"10.1016\/j.jhepr.2024.101313","article-title":"Statin use and liver-related prognosis among patients with MASLD","volume":"7","author":"Yun","year":"2025","journal-title":"JHEP Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta\u2010analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1884657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:56:30Z","timestamp":1784811390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1884657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":63,"alternative-id":["10.3389\/fphar.2026.1884657"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1884657","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1884657"}}